These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
317 related items for PubMed ID: 17178213
1. Idiotypic and anti-idiotypic elastin autoantibodies: Implications for IVIg and pregnancy loss. Konova E, Atanasova M, Stoykov S, Velkova A, Shoenfeld Y. J Autoimmun; 2007 Feb; 28(1):46-54. PubMed ID: 17178213 [Abstract] [Full Text] [Related]
2. Anti-elastin antibodies and elastin turnover in normal pregnancy and recurrent pregnancy loss. Konova E, Aleksovska T, Atanasova M, Georgieva M, Todorova K, Lukanov T, Shoenfeld Y. Am J Reprod Immunol; 2009 Feb; 61(2):167-74. PubMed ID: 19143680 [Abstract] [Full Text] [Related]
3. Anti-idiotypes against antiphospholipid antibodies are present in normal polyspecific immunoglobulins for therapeutic use. Caccavo D, Vaccaro F, Ferri GM, Amoroso A, Bonomo L. J Autoimmun; 1994 Aug; 7(4):537-48. PubMed ID: 7980854 [Abstract] [Full Text] [Related]
4. Anti-idiotypes against autoantibodies and alloantibodies to VIII:C (anti-haemophilic factor) are present in therapeutic polyspecific normal immunoglobulins. Rossi F, Sultan Y, Kazatchkine MD. Clin Exp Immunol; 1988 Nov; 74(2):311-6. PubMed ID: 3147154 [Abstract] [Full Text] [Related]
5. Normal immunoglobulin G (IgG) for therapeutic use (intravenous Ig) contain antiidiotypic specificities against an immunodominant, disease-associated, cross-reactive idiotype of human anti-thyroglobulin autoantibodies. Dietrich G, Kazatchkine MD. J Clin Invest; 1990 Mar; 85(3):620-5. PubMed ID: 2312717 [Abstract] [Full Text] [Related]
6. [Intravenous immunoglobulin (IVIG) as treatment for recurrent pregnancy loss (RPL)]. Sapir T, Carp H, Shoenfeld Y. Harefuah; 2005 Jun; 144(6):415-20, 454, 453. PubMed ID: 15999561 [Abstract] [Full Text] [Related]
7. The efficacy of specific IVIG anti-idiotypic antibodies in antiphospholipid syndrome (APS): trophoblast invasiveness and APS animal model. Blank M, Anafi L, Zandman-Goddard G, Krause I, Goldman S, Shalev E, Cervera R, Font J, Fridkin M, Thiesen HJ, Shoenfeld Y. Int Immunol; 2007 Jul; 19(7):857-65. PubMed ID: 17576752 [Abstract] [Full Text] [Related]
10. Autoantibodies to plasminogen and tissue plasminogen activator in women with recurrent pregnancy loss. Bu C, Zhang C, Li Z, Gao L, Xie Z, Cai G. Clin Exp Immunol; 2007 Jul; 149(1):31-9. PubMed ID: 17425656 [Abstract] [Full Text] [Related]
11. Normal polyspecific immunoglobulin G (IVIg) in the treatment of autoimmune diseases. Hurez V, Kaveri SV, Kazatchkine MD. J Autoimmun; 1993 Dec; 6(6):675-81. PubMed ID: 8155249 [Abstract] [Full Text] [Related]
12. A disease-specific fraction isolated from IVIG is essential for the immunosuppressive effect of IVIG in experimental autoimmune myasthenia gravis. Fuchs S, Feferman T, Meidler R, Margalit R, Sicsic C, Wang N, Zhu KY, Brenner T, Laub O, Souroujon MC. J Neuroimmunol; 2008 Feb; 194(1-2):89-96. PubMed ID: 18178258 [Abstract] [Full Text] [Related]
14. Immunomodulatory effects of intravenous immunoglobulins as a treatment for autoimmune diseases, cancer, and recurrent pregnancy loss. Sapir T, Blank M, Shoenfeld Y. Ann N Y Acad Sci; 2005 Jun; 1051():743-78. PubMed ID: 16127014 [Abstract] [Full Text] [Related]
17. Autoantibodies in Argentine women with recurrent pregnancy loss. Bustos D, Moret A, Tambutti M, Gogorza S, Testa R, Ascione A, Prigoshin N. Am J Reprod Immunol; 2006 Mar; 55(3):201-7. PubMed ID: 16451354 [Abstract] [Full Text] [Related]